Eli Lilly and Boehringer Ingelheim cut investment in Germany due to proposed healthcare spending reductions, impacting the pharmaceutical industry and insurance subsidies.

FDA approves prescription leucovorin for autism treatment; HHS addresses investment and regulatory concerns involving CMS administrator Dr. Mehmet Oz amid public discourse.